James Brophy, MD, FRCP, FACC, PhD
GIM/FP/GP:
Endocrinology:
Brophy J. Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality. Ann Intern Med. 2017;166:JC7. doi: 10.7326/ACPJC-2017-166-2-007
Download citation file:
© 2018
Published: Ann Intern Med. 2017;166(2):JC7.
DOI: 10.7326/ACPJC-2017-166-2-007
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by: